Skip to main content
Premium Trial:

Request an Annual Quote

AxCell s Becker Tapped to Run Cytogen as CEO Steps Down

For an updated version of this article, click here.


NEW YORK, Dec. 17 - Cytogen today said it has tapped AxCell chief Michael Becker to replace Joseph Reiser, who stepped down as president and CEO "for personal reasons" this afternoon.


Additionally, Lawrence Hoffman has quit as vice president and CFO, and Thu Dang, Cytogen's director of finance and 14-year veteran of the company, has been promoted to VP of finance.


It was not immediately clear whether Becker's ascension will affect AxCell, or if he will run both firms.


"As we look ahead to the next phase in Cytogen's evolution, I believe it is appropriate that Michael take on an expanded role as CEO," said Reiser, who will stay on as a board member.


Beside running AxCell, Becker was VP of business development and investor relations at Cytogen, where he has now been named to the board.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.